Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase
            III
            Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors

Faculty Opinions recommendation of Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734268130.793576219 ◽

2020 ◽

Author(s):

Pedro Machado

Keyword(s):

Tumor Necrosis ◽

Axial Spondyloarthritis ◽

Controlled Trial ◽

Phase Iii ◽

Inadequate Response ◽

Tumor Necrosis Factor Inhibitors ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

10.1002/art.22025 ◽

2006 ◽

Vol 54 (9) ◽

pp. 2793-2806 ◽

Cited By ~ 1041

Author(s):

Stanley B. Cohen ◽

Paul Emery ◽

Maria W. Greenwald ◽

Maxime Dougados ◽

Richard A. Furie ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis ◽

Phase Iii ◽

Primary Efficacy ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Factor Therapy ◽

Faculty Opinions recommendation of Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718325315.793492809 ◽

2014 ◽

Author(s):

Ronald van Vollenhoven

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis ◽

Phase Iii ◽

Primary Efficacy ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Factor Therapy ◽

Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials

Clinical Rheumatology ◽

10.1007/s10067-019-04595-1 ◽

2019 ◽

Vol 38 (10) ◽

pp. 2765-2776 ◽

Cited By ~ 6

Author(s):

Yanrong Huang ◽

Yong Fan ◽

Yang Liu ◽

Wenhui Xie ◽

Zhuoli Zhang

Keyword(s):

Tumor Necrosis ◽

Active Rheumatoid Arthritis ◽

Meta Analysis ◽

Phase Iii ◽

Controlled Trials ◽

Inadequate Response ◽

Tumor Necrosis Factor Inhibitors ◽

Efficacy And Safety ◽

Randomized Controlled ◽

Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

10.1002/art.27348 ◽

2010 ◽

Vol 62 (4) ◽

pp. 917-928 ◽

Cited By ~ 76

Author(s):

Joel Kremer ◽

Christopher Ritchlin ◽

Alan Mendelsohn ◽

Daniel Baker ◽

Lilianne Kim ◽

...

Keyword(s):

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Active Rheumatoid Arthritis ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Α ◽

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial

10.1002/art.33353 ◽

2012 ◽

Vol 64 (2) ◽

pp. 360-370 ◽

Cited By ~ 41

Author(s):

P. P. Tak ◽

P. J. Mease ◽

M. C. Genovese ◽

J. Kremer ◽

B. Haraoui ◽

...

Keyword(s):

Tumor Necrosis ◽

Tumor Necrosis Factor Inhibitor ◽

Phase Iii ◽

Inadequate Response ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Parallel Group ◽

Factor Inhibitor ◽

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumor necrosis factor inhibitors: OPAL Beyond, a randomized, double blind, placebo-controlled, phase 3 trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2017.04.451 ◽

2017 ◽

Vol 76 (6) ◽

pp. AB114

Keyword(s):

Tumor Necrosis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Inadequate Response ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Erratum: Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

10.1002/art.27747 ◽

2010 ◽

Vol 62 (10) ◽

pp. 3130-3130 ◽

Cited By ~ 2

Author(s):

Joel Kremer ◽

Christopher Ritchlin ◽

Alan Mendelsohn ◽

Daniel Baker ◽

Lilianne Kim ◽

...

Keyword(s):

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Active Rheumatoid Arthritis ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Α ◽

OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial

10.1136/annrheumdis-2017-eular.2443 ◽

2017 ◽

Cited By ~ 3

Author(s):

DD Gladman ◽

WFC Rigby ◽

VF Azevedo ◽

F Behrens ◽

R Blanco ◽

...

Keyword(s):

Tumour Necrosis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Inadequate Response ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Ustekinumab in active psoriatic arthritis including patients previously treated with anti–tumor necrosis factor agents: Week 24 results from PSUMMIT 2, a phase III, multicenter, double-blind, placebo-controlled study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2012.12.895 ◽

2013 ◽

Vol 68 (4) ◽

pp. AB217

Keyword(s):

Psoriatic Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Phase Iii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Previously Treated ◽